Lei Jianping on April 26
Shenzhen Mindray Biomedical Electronics Co., Ltd. (stock code: 300760, stock abbreviation: Mindray Medical) released its financial results today. According to the financial report, Mindray Medical's revenue in 2023 will be 34.932 billion yuan, an increase of 15% from 30.366 billion yuan in the same period last year.
During the reporting period, the company continued to maintain high R&D investment, with R&D investment of 3.779 billion yuan, a year-on-year increase of 18.43%, accounting for 10.82% of revenue.
Mindray's net profit in 2023 was RMB11.582 billion, an increase of 20.56% from RMB9.6 billion in the same period last year, and its net profit after deducting non-profits was RMB11.434 billion, an increase of 20% from RMB9.525 billion in the same period last year.
Among them, Mindray Medical's revenue in the fourth quarter of 2023 will be 7.628 billion yuan, with a net profit of 1.748 billion yuan, and a net profit of 1.748 billion yuan after deducting non-profits.
Based on the company's total share capital of 1,212,441,394 shares as of December 31, 2023, Mindray Medical will distribute a cash dividend of RMB 15 (tax included) to all shareholders for every 10 shares, and give 0 bonus shares (tax included), without converting capital reserve into share capital.
After years of development, the company has become the world's leading provider of medical devices and solutions, and its products are exported to more than 190 countries and regions.
Headquartered in Shenzhen, China, Mindray has 62 overseas subsidiaries in about 40 countries in North America, Europe, Asia, Africa, Latin America and other regions, 26 subsidiaries and more than 30 branches in China, and has established a R&D and innovation platform based on global resource allocation, with 12 R&D centers in Shenzhen, Wuhan, Nanjing, Beijing, Xi'an, Chengdu, Hangzhou, Silicon Valley, New Jersey, Minnesota, Hyperpeptide and Desay, forming a huge global R&D. Marketing and service network.
In the domestic market, Mindray's products have fully covered the three major business areas of life information and support, in vitro diagnostics, and medical imaging, and at the same time realized integrated, integrated, and digital intelligence solutions from low-end to high-end, from departments to the whole hospital. At the same time, with the advantages of rich product solutions and information technology, the company's products have been more widely recognized in large public hospitals, especially in the shortcomings, hospital reconstruction and expansion and strategic reserve projects have greater competitive advantages, so that the company has won a number of provincial and above large-scale political procurement bidding projects.
During the reporting period, the company's products covered nearly 110,000 medical institutions and more than 99% of tertiary hospitals in China, and the product penetration rate was further improved.
In the international market, Mindray has benefited from its long-term market cultivation and brand building over the past 20 years, and has introduced the company's products in the world's top hospitals in North America and Western Europe.
———————————————
Lei Di was founded by Lei Jianping, a media person, if it is reprinted, please indicate the source.